Abstract. Pathological complete response is achievable with mFOLFOX6 plus cetuximab therapy for unresectable colorectal cancer with multiple paraaortic lymph node metastases (mCRC) despite right-sided colonic origin. A 62-year-old woman with synchronous paraaortic lymph node metastases of transverse colon cancer was treated with mFOLFOX6 plus cetuximab as first-line therapy. The tumor size was markedly decreased following 6 courses of chemotherapy, and all lymph node metastases had disappeared. The patient then underwent conventional right hemicolectomy with D3 lymph node dissection plus sampling excision of the paraaortic lymph nodes. The pathological diagnosis was a complete response. The patient is currently alive 5 years after surgery with no signs of recurrence. The present study reported the apparent effectiveness of conversion therapy (surgery) with combination treatment with mFOLFOX6 plus cetuximab and radical surgery. We hypothesized that patients with different types of mCRC of right-sided colon origin may be effectively treated with anti-EGFR monoclonal antibodies.
Introduction
Recently, chemotherapy for colorectal cancer has progressed markedly. In particular, treatment for unresectable metastatic colorectal cancer (mCRC) has notably improved with the development of FOLFOX and FOLFIRI therapies (1) . Furthermore, combination of monoclonal antibody therapies, including anti-epidermal growth factor receptor (EGFR) monoclonal antibody or anti-vascular endothelial growth factor (VEGF) monoclonal antibody therapy with chemotherapeutic cytotoxic drugs has made treatment more effective and useful for patients with unresectable mCRC (2-6). However, curing unresectable mCRC is difficult with chemotherapy alone. At present, effective novel chemotherapeutic agents may now convert unresectable mCRC with liver metastases into resectable disease (conversion therapy) (7).
Case report
A 62-year-old female with occult blood in her stool was referred to Gifu University Hospital (Gifu, Japan) for evaluation and treatment. The patient had a previous history of appendectomy and cesarean section. Colonoscopy revealed a superficial elevated tumor in the transverse colon (Fig. 1) , and biopsy results indicated adenocarcinoma. An abdominal computed tomography (CT) scan revealed increased transverse colon wall thickness and swollen lymph nodes in the mesocolon, and along the superior mesenteric artery and aorta. A fluorine-18 fluorodeoxyglucose (FDG) positron emission tomography scan revealed FDG accumulations in the primary lesion and multiple swollen lymph nodes (Fig. 2) . The laboratory data revealed high levels of tumor markers, CEA (1.5 ng/ml) and CA19-9 (221.4 U/ml). The initial diagnosis was Stage IVA [T3 N2b M1a (lymph nodes)] according to the Union for international cancer control TNM classification of malignant tumors (8th edition) (8) . Colonic stenosis in this patient was not severe; therefore, chemotherapy without surgery was planned for this unresectable case. The first course consisted only of mFOLFOX6 [l-leucovorin 200 mg/m 2 administered simultaneously with oxaliplatin 85 mg/m 2 , followed by a 400-mg/m 2 bolus of fluorouracil (5-FU) on day 1 and then 2,400 mg/m 2 5-FU as an intravenous infusion over 46 h, every 2 weeks], but the tumor marker levels increased markedly. As a genetic analysis revealed presence of the wild-type KRAS gene, mFOLFOX6 plus cetuximab (400 mg/m 2 loading dose on day 1 and then 250 mg/m 2 weekly) were administered for the second course. After 6 courses of chemotherapy were performed, the tumor marker levels had declined markedly, and all lymph node metastases had disappeared on enhanced CT scanning, which indicated clinical complete response according to the Response Evaluation Criteria in Solid Tumors (Fig. 3 ). Therefore, a conventional right hemicolectomy with D3 lymph node dissection plus sampling excision of the paraaortic lymph nodes was performed. The operative specimen was fixed in 10% buffered formalin for 24 h, then processed to paraffin embedded tissue. Paraffin sections were cut to 4 µm in thickness. Sections were deparaffinized by xylene followed by hydrolyzed with ethanol solution series. Antigen retrieval was performed by heating in antigen retrieval solution (Ventana Medical Systems, Inc., Tucson, AZ, USA) at 95˚C for 35 min. Histological examination of the specimen did not reveal any malignant cells in the colon wall or in the mesocolon lymph nodes (Fig. 4) . The pathological diagnosis was a complete response. The patient is currently alive 5 years after surgery with no signs of recurrence.
Discussion
The prognosis of mCRC has significantly improved in recent years with the development of more effective surgical approaches, and more efficacious chemotherapy regimens, including FOLFOX or FOLFIRI rendering more patients as surgical candidates (9) . Chemotherapy is now able to convert unresectable colorectal liver metastasis into resectable disease (conversion chemotherapy), and prior 'rules of resectability' are being challenged (10) . This has increased the rates of resectability from 10-15% to up to 20-30% with 5-and 10-year overall survival (OS) rates of ~33 and 23%, respectively. For example, patients who undergo liver resection and survive beyond 10 years appear to be cured in almost all cases (11). In addition, CRC patients with lung metastases or paraaortic lymph node metastases who undergo radical resection are expected to have improved survival (12) (13) (14) (15) (16) . The concepts of early tumor shrinkage and deepness of response were also previously assessed in first-line trials with anti-EGFR monoclonal antibodies for patients with KRAS wild-type mCRC (17, 18) . Therefore, we hypothesized that anti-EGFR monoclonal antibodies are key drugs for the conversion of unresectable and metastatic colorectal metastasis into resectable disease.
Recently, primary tumor location, whether of right-or left-sided origin, has been investigated for its role in aiding in predicting outcomes. OS following anti-EGFR monoclonal antibody treatment with CALGB/SWOG80405 (19) was significantly different between right-and left-sided origins. In particular, OS with anti-EGFR monoclonal antibody treatment was significantly poorer for right-sided origins and significantly improved for left-sided origins. However, Holch et al (20) reported a meta-analysis of OS and progression-free survival of patients with unresectable mCRC treated with CALGB/SWOG80405, FIRE-3 or PEAK (19, 21, 22) . In a comparison of anti-EGFR and anti-VEGF therapy, patients with RAS wild-type left-sided origins received a markedly greater benefit from anti-EGFR-based therapy. These aforementioned studies (19, 21, 22) also reported the analysis of overall response rates in terms of the impact of primary tumor location on therapy with either anti-EGFR or anti-VEGF antibodies combined with standard chemotherapy. The results demonstrated a significantly improved overall response rate with anti-EGFR monoclonal antibody treatment for tumors of right-sided origins. These results also indicated that BRAF mutant, microsatellite instability (MSI)-high, and CpG island methylator phenotype-1 tumors are expected to occur more frequently in colon cancer of right-sided origin. In the present case, the treatment regimen of mFOLFOX6 plus cetuximab was effective despite the right-sided origin of the colon cancer.
Therefore, combination chemotherapy and surgical resection may potentially cure transverse colon cancer with multiple paraaortic lymph node metastases. It is important to evaluate the rate of tumor shrinkage from the beginning of the first-line treatment until 6 courses of anti-EGFR monoclonal antibody have been administered and to determine whether conversion therapy (surgery) is possible (23) . We hypothesized that patients with different types of mCRC of right-sided origin may be effectively treated with anti-EGFR monoclonal antibodies. At present, patients with poor clinical outcomes can be expected to receive another treatment regimen of anti-VEGF monoclonal antibodies (24, 25) .
In conclusion, the regimen of mFOLFOX6 plus cetuximab was effective in treating the patient with mCRC in the present study, despite its right-sided origin. We hypothesized that even mCRC of right-sided origin may be effectively treated with anti-EGFR monoclonal antibody treatment at uniform rates. Anti-PDL-1 antibody treatment is recommended for patients with MSI-high tumors in the National Comprehensive Cancer Network and European Society for Medical Oncology guidelines (26, 27) . Therefore, not only Ras-and BRAF-type colorectal tumors, but also tumors of every genomic type, may be treated in this manner in the future.
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